Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) by Untch, Michael et al.
Consensus  · Konsens
Breast Care 2011;6:144–152 Published online: April 29, 2011
DOI: 10.1159/000327999
© 2011 S. Karger GmbH, Freiburg
1661-3791/11/0062-0144$38.00/0
Accessible online at: 
www.karger.com/brc
Fax +49 761 4 52 07 14
Information@Karger.de
www.karger.com
BreastCare
Zurich Consensus: Statement of German Experts on  
St. Gallen Conference 2011 on Primary Breast Cancer 
(Zurich 2011)
Michael Untch1* Bernd Gerber2* Volker Möbus3* Andreas Schneeweiss4* 
Christoph Thomssen5* Gunter von Minckwitz6* Matthias W. Beckmann7 Jens-Uwe Blohmer8 
Serban-Dan Costa9 Klaus Diedrich10 Ingo Diel11 Wolfgang Eiermann12 Klaus Friese13 
Nadia Harbeck14 Jörn Hilfrich15 Christian Jackisch16 Wolfgang Janni17 Fritz Jänicke18 
Walter Jonat19 Manfred Kaufmann20 Marion Kiechle21 Uwe Köhler22 Rolf Kreienberg23 
Nicolai Maass24 Norbert Marschner25 Ulrike Nitz26 Anton Scharl27 Diethelm Wallwiener28
1Klinik für Gynäkologie, HELIOS Klinikum Berlin Buch, 2Universitätsfrauenklinik Rostock, 3Frauenklinik am Klinikum Frankfurt-Höchst, 
Frankfurt/M., 4Nationales Centrum für Tumorerkrankungen (NCT) und Universitätsfrauenklinik Heidelberg, 5Universitätsklinik und Poli-
klinik für Gynäkologie, Halle (Saale), 6German Breast Group, Neu-Isenburg, 7Universitätsfrauenklinik Erlangen, 8St. Gertrauden Kran-
kenhaus Berlin, 9Universitätsfrauenklinik Magdeburg, 10Universitätsfrauenklinik Lübeck, 11Gemeinschaftspraxis Gynäkologie und Geburts-
hilfe, Mannheim, 12Frauenklinik, Rotkreuzklinikum München, 13Universitätsfrauenklinik München, 14Brustzentrum Universitätsfrauenklinik 
Köln, 15Eilenriede-Klinik, Hannover, 16Klinik für Gynäkologie und Geburtshilfe, Klinikum Offenbach, 17Universitätsfrauenklinik Düsseldorf, 
18Klinik und Poliklinik für Gynäkologie des Universitätsklinikums Hamburg-Eppendorf, 19Universitätsfrauenklinik Kiel, 20Universitäts-
frauenklinik Frankfurt/Main, 21Frauenklinik Rechts der Isar der Technischen Universität München, 22Klinik für Gynäkologie und Geburtshilfe 
am Klinikum St. Georg gGmbH, Leipzig, 23Universitätsfrauenklinik Ulm, 24Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum 
Aachen, 25Gemeinschaftspraxis für interdisziplinäre Onkologie und Hämatologie, Freiburg i. Br., 26Evangelisches Krankenhaus Bethesda, 
Mönchengladbach, 27Frauenklinik, Klinikum St. Marien, Amberg, 28Universitätsfrauenklinik Tübingen, Germany
Schlüsselwörter
Frühes Mammakarzinom · Endokrine Therapie ·  
neoadjuvante Therapie · Zielgerichtete Therapie ·  
Prädiktive und prognostische Marker
Zusammenfassung
Alle 2 Jahre findet in St.-Gallen die internationale Konsen-
suskonferenz zur Behandlung des primären Mammakar-
zinoms statt. Vor dem Hintergrund, dass das Konzept der 
St.-Gallen-Konsensuskonferenz vor allem ein internatio-
nales Meinungsbild widerspiegelt, erscheint es sinnvoll, die 
Abstimmungsergebnisse für den Therapiealltag in Deutsch-
land zu adaptieren. Eine deutsche Arbeitsgruppe von 28 
Brustkrebsexperten, darunter 3 Mitglieder des internationa-
len St. Gallen-Panels, hat daher die Abstimmungsergeb-
nisse der diesjährigen St.-Gallen-Konsensuskonferenz (2011) 
aus deutscher Sicht kommentiert. Inhaltlicher Schwerpunkt 
der diesjährigen St.-Gallen-Konferenz war die Tumorbiolo-
gie als Ausgangspunkt für die individuelle Therapieent-
scheidung. Intensiver Diskussionsbedarf bestand bei der 
klinischen Relevanz prädiktiver und prognostischer Fakto-
ren und den möglichen Konsequenzen für die Therapie-
entscheidung. So fokussierten insbesondere die Fragen zur 
Indikation einer adjuvanten Chemotherapie auf die Bedeu-
tung des molekularen Phänotyps des Tumors. Wichtige 
Diskussionspunkte waren darüber hinaus der Stellenwert 
der kompletten Axilladissektion und der Einsatz der be-
schleunigten Gesamt-Brust-Bestrahlung. 
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Summary
Every 2 years, the International Consensus Conference on 
the Treatment of Primary Breast Cancer takes place in 
St. Gallen. Given that the concept of the St. Gallen Consen-
sus Conference mainly reflects an international opinion, it 
appears useful to adapt the results of the vote for everyday 
therapy in Germany. A German working group comprising 
28 breast cancer experts, amongst whom there are 3 mem-
bers of the international St. Gallen panel, has therefore 
commented on this year’s St. Gallen Consensus Conference 
(2011) from the German viewpoint. The focus of interest of 
this year’s St. Gallen Conference was tumour biology as the 
starting point for decisions regarding individual therapy. 
There was an intensive discussion in relation to the clinical 
relevance of predictive and prognostic factors and possible 
consequences for decisions regarding therapy. Therefore, 
questions concerning the indication for adjuvant chemother-
apy focused especially on the significance of the molecular 
phenotype of the tumour. In addition, important points for 
discussion were also the value of complete axillary dissec-
tion and the use of accelerated complete breast irradiation.
*Writing committee
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Prognostic and Predictive Factors
Characterising Phenotypes
In response to the question of whether the various subtypes of 
breast cancer can be defined exclusively – that is without the 
use of a multi-gene assay – on the basis of immunohistology 
utilizing currently available and reproducible pathology pa-
rameters, such as hormone receptor status, HER2 status, 
grading and Ki-67, a clear majority of panellists in St. Gallen 
responded with ‘yes’. The German working group agrees, but 
notes that the proliferation factor Ki-67 has not been a stand-
ard marker until now, however, it can be of value in some 
cases – in accordance with the AGO recommendation 2011. 
Apart from methodological problems in the measurement of 
Ki-67, the cut-off values have still not been unambiguously 
defined. It is accepted that a Ki-67 value of ≤ 10% measured 
using immunohistochemical techniques shows a low prolifera-
tion rate and is associated with a good prognosis. Ki-67 deter-
mination is therefore suitable, for example in order to better 
differentiate between luminal A (Ki-67 ≤ 10%) and luminal 
B type. What remains unclear is the cut-off value for high pro-
liferation. Hence, there still is a lack of data from prospective 
randomized studies, as well as a standardized determination 
of Ki-67.
Accordingly, the St. Gallen panellists and the German 
experts agree that hormone receptor expression (oestrogen 
receptor (ER)+/progesterone receptor (PgR)–) and/or a high 
level of Ki-67 expression and/or G3 grading, as well as HER2 
positivity are the best available markers to differentiate lumi-
nal B from luminal A type. The luminal A type can be defined 
by a clear positive ER and PgR status (ER+/PgR+), the ab-
sence of HER2 overexpression and a low Ki-67 value. The 
German experts drew attention, however, to the fact that 
currently no therapeutic consequences can be directly con-
cluded on the basis of the typing as luminal A or B alone. The 
St. Gallen panellists confirmed this in a later vote on the clini-
cal value of molecular gene expression analyses. The marker 
for the definition of a carcinoma of the breast of the basal 
type (basal-like), cytokeratin 5 and 6 (CK5/6), and/or epider-
mal growth factor receptor (EGFR) expression, have not yet 
been validated in clinical routine.
Introduction
The St. Gallen Consensus Conference on the Diagnosis 
and Treatment of Primary Breast Cancer has worldwide im-
portance. The panel of this year’s 12th St. Gallen Consensus 
Conference (March 16–19, 2011) comprises 51 experts from 
19 countries, including 4 representatives from Germany. The 
recommendations of the conference are based on the vote of 
panellists who represent different specialities and different 
countries from all continents of the world with very different 
health systems and resources. This framework justifies the 
consensus essentially reflecting the opinion of these experts, 
although published evidence-based data are the basis for 
individual decisions. It appears appropriate to comment on 
the results of the voting at the conference from a German 
perspective. A German working group consisting of 28 breast 
cancer experts therefore interpreted the results of the votes 
in St. Gallen related to everyday clinical practice in Germany. 
Because of country-specific differences, not all of the ques-
tions raised for voting in St. Gallen have equal clinical rele-
vance for the therapeutic situation in Germany.
The focus of this year’s St. Gallen Consensus Conference 
was tumour biology and the questions of influence of pheno-
type of the tumour on individual therapy decisions. The basis 
are the subtypes illustrated in table 1 which, in keeping 
with current knowledge, are associated with different tumour 
biology and a different disease course. In addition, surgical 
treatment, radiation therapy and systemic treatment were 
discussed. The questions raised for voting were answered by 
the panellists with ‘yes’ (agreed) or ‘no’ (rejected) or ‘abstain/
do not know’.
The German group drew attention to two points: i) With 
increasing importance of tumour biology or phenotyping of 
the tumour, histopathology has gained importance. Validated 
and standardised quality assurance concepts in pathology are 
more important than ever; ii) Participation in controlled clini-
cal studies has a high value and should be further pursued. 
This also applies to numerous therapeutic questions, which 
were addressed in St. Gallen. However, individual studies will 
only be cited in exceptions.
Table 1. Overview of currently relevant molecular subtypes of breast cancer; subtypes defined on the basis of gene expression are frequently not 
exclusively associated with the specified marker profile
Basal-like BRCA Basal-like, sporadic HER2 + Luminal B Luminal A
ER–/PgR– ER–/PgR– ER–/PgR– ER+/PgR– ER+/PgR+
G3 G3 G3 G1,2 G1
Ki-67 50–60% Ki-67 50–60% Ki-67 40–50% Ki-67 5–20% Ki-67 5%
HER2–/EGFR+ HER2–/EGFR+ HER2+ HER2– HER2–
BRCA1/2+ BRCA1/2–
P53/cMYC↑ P53/cMYC↑
ER = Oestrogen receptor; PgR = progesterone receptor; EGFR = epidermal growth factor receptor.
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German perspective, participation in ongoing studies is 
recommended as long as no prospective data are available. 
Oncotype DX should be used outside clinical studies only 
in individual cases in addition to the clinical and histopatho-
logical parameters. The test can be helpful, for example in 
patients with positive hormone receptor and negative HER2 
status and only 1–3 affected lymph nodes (pN0, pN1a). Here, 
retrospective data show that patients with a low recurrence 
score (applies only to pN0 and pN1a) or a low and intermedi-
ate recurrence score (applies only to pN0) have no significant 
advantage from adjuvant chemotherapy [1, 2]. Both tests are 
not covered by medical insurance.
uPA/PAI-1 Determination
The determination of uPA/PAI-1 as a predictive factor for or 
against the use of chemotherapy was rejected in St. Gallen by 
the majority of panellists (50%) with 23% positive votes and 
27% abstentions. The German experts did not agree with this 
statement. Based on the available data (LOE 1a) uPA/PAI-1 
are valid standardised and evidence-based prognostic and 
predictive factors for patients with node-negative breast 
cancer and intermediate risk profiles (e.g. pN0 G2), which is 
substantiated by prospective data. This is also in accordance 
with the AGO recommendation 2011. uPA/PAI-1 must be 
determined from fresh tissue.
Local Therapy 
Axillary Dissection
The focus of the voting on locoregional therapy were the 
value of complete axillary dissection and the type of local 
breast irradiation. There was no voting on surgery of the 
breast.
With a clear majority (71%), the St. Gallen panellists re-
jected immunohistochemical assessment of sentinel lymph 
nodes (SLN) as a routine procedure. More than 90% of 
panellists considered exclusive immunohistochemical detec-
tion of isolated tumour cell clusters (ITC or pN0(i+)) not to 
be an indication for complete axillary dissection, independent 
of whether the patients have a mastectomy or breast-conserv-
ing operation. The German experts agree and reinforce the 
fact that immunohistochemical assessment of the SLN has no 
clinical significance. 
For patients with a breast-conserving operation, the 
St. Gallen panellists, in contrast to the vote taken 2 years ago, 
viewed neither the evidence of ITCs nor micrometastases 
(pN1mi) in the SLN as an indication for a complete axillary 
dissection. It has been criticised that the definitions of ITC 
and micrometastases used in the questions in St. Gallen did 
not correspond to the international UICC classification. How-
ever, as the majority of panellists rejected a complete axillary 
dissection up to a focal size of 2 mm ( = upper cut-off for mi-
crometastases) in the SLN, the result of the vote is essentially 
HER2 Overexpression
In order to define HER2 positivity, 68% of the St. Gallen 
panellists voted for maintaining the FDA definition: accord-
ingly, more than 10% of the tumour cells must be immunohis-
tochemically positive or in fluorescence in situ hybridisation 
(FISH) there must be a HER2 gene/centromere 17 ratio 
greater than 2.0. The FDA definition is based on the inclusion 
criterion of adjuvant trastuzumab studies in patients with 
HER2-positive breast cancer. The German working group 
recommended to use the AGO recommendation (2011) or the 
ASCO/CAP guidelines (2007) as an orientation. Accordingly, 
HER2-positivity is defined as ≥ 30% immunohistochemically 
detected HER2-positive tumour cells (IHC3+) or a FISH 
ratio ≥ 2.2. In the case of a HER2 expression > 10 to 
< 30% (IHC2+), a FISH (or CISH) analysis is additionally 
recommended.
Molecular Gene Expression Analysis
The German experts agreed with the majority of the St. Gal-
len panellists that the decision regarding therapy should not 
be made on the basis of a molecular gene expression analysis 
and the tumour subtype defined in relation to this. They drew 
attention to the fact that an intrinsic tumour type is not a 
standardised predictive factor and that allocation to a particu-
lar tumour type on the basis of a gene expression profile is not 
qualified for the indication of a particular adjuvant systemic 
therapy. This is also not a predictor for response to a particu-
lar chemotherapy regimen or specific cytostatics. With this 
opinion, the St. Gallen panellists and the German experts 
confirmed that currently, as a rule, the phenotype can be 
determined with a sufficient degree of certainty in everyday 
clinical practice by non-genetic tests such as, for example, 
grading, hormone receptor status and HER2 status, as well as 
optionally Ki-67 determination.
In contrast to the situation 2 years ago, the 2 molecular 
tests Oncotype DX® (Genomic Health Inc., Redwood City, 
CA, USA) and Mammaprint® (Agendia, Amsterdam, The 
Netherlands) were evaluated differently by the panellists, al-
though no new study data have become available. While a 
clear majority (84%) of panellists voted for Oncotype DX to 
be used (where available) in patients with hormone-sensitive 
breast cancer in order to predict the response to CMF chemo-
therapy (cyclophosphamide, methotrexate, 5-fluorouracil), 
the majority of panellists (64%) rejected the use of Mamma-
print in this context. The St. Gallen panel adopted no position 
regarding the questions in which patients or how frequently 
such an additional determination is necessary.
The differing vote of the St. Gallen panellists is debatable 
since comparable data are available for both test systems. The 
German experts explain the different evaluations by logistic 
problems, as Mammaprint is performed on fresh tissue. The 
positive vote for Oncotype DX was discussed by the German 
experts as a matter of controversy because for both tests 
only data from retrospective studies are available. From the 
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can be omitted. The German working group agreed, and 
pointed out that this shouldtake into account benefits and side 
effects. A majority of the St. Gallen panellists voted that 
in low-grade DCIS postoperative radiation can be omitted. 
The German experts were against this vote and recommended 
an individual side effect/benefit assessment with the limitation 
that low-risk patients cannot always be unambiguously 
identified.
In relation to the type of radiation for an invasive carci-
noma, the panellists considered accelerated whole breast 
radiation therapy (WBRT) with a clear majority (92%) to be 
an acceptable option. The German working group agreed, but 
stated that accelerated WBRT should be limited to particular 
clinical situations [4]. An advantage of accelerated WBRT 
is the clearly shortened duration of therapy from 6 weeks to 
16 days.
There was no unity in the results of voting in St. Gallen 
with regard to the question of whether standard irradiation 
of the breast should be preferentially used in patients with 
invasive breast cancer and extended vascular invasion. The 
controversial results of voting make clear that, at present, 
there are no prospective data with regard to this question. 
The German experts therefore expressed the opinion that this 
should be decided in the individual case, taking into account 
the overall clinical situation and weighing up the individual 
side effect/benefit situation.
The majority of the St. Gallen panellists (49 vs. 36%) voted 
for intra-operative partial breast radiation therapy (PBRT) 
following a breast-conserving operation as a definitive radia-
tion therapy to be sufficient so that no external radiation 
(boost, complete breast radiation) is necessary. The German 
experts discussed this point controversially. Because of the 
low event rate (local relapse) and the relatively short post-
observation period, no general recommendation can be made 
for PBRT. Further study results must be awaited. Participa-
tion in the studies, for example in the Targit studies, is recom-
mended. There is unity that intra-operative PBRT in the case 
of breast-conserving operations is an acceptable alternative to 
external boost-radiation of the tumour bed. In addition, the 
St. Gallen panellists viewed (intra-operative) PBRT as an 
option for older patients (> 70 years). The German experts 
agree with this as a ‘can’ option for individual cases. The 
St. Gallen view of whether (intra-operative) PBRT is also an 
option for patients who, because of an earlier lymphoma 
disease, have received total nodal irradiation was contro-
versial. The German experts recommend discussing this with 
the patient and colleagues who are specialists in radiation 
therapy. A second radiation therapy is not fundamentally 
excluded.
Radiation Therapy Following Mastectomy
There is agreement that adjuvant radiation for patients with 
4 and more affected lymph nodes, who have undergone 
mastectomy, is standard. No general recommendation was 
clear: following a breast-conserving operation, in the case of a 
clinically and sonographically normal axilla, despite evidence 
of ITC or micrometastases in the SLN, complete axillary dis-
section is not recommended.
The German experts agree with this statement, in conform-
ity with the current AGO recommendation (fig. 1), and state 
their view accordingly: a complete axillary dissection can be 
omitted when the following conditions are present: clinically 
and sonographically normal axillary lymph node status (cN0), 
≤ 2 tumour-infiltrated SLN, breast-conserving operation, 
cT1/2, tangential radiation field of the breast, and adequate 
adjuvant systemic therapy. The German experts emphasised 
that these patients must be informed about the data situation. 
An extra-radiation therapy field of the axilla is not indicated 
[3]. In the case of patients who have undergone a mastectomy 
and who have a positive SLN biopsy, there is still an indica-
tion for axillary lymphadenectomy. The working group 
also mentioned that internationally validated definitions of 
isolated tumour cell clusters and micrometastases should be 
respected. The procedure to be followed in the case of 
macrometastases in the SLN was only voted on in St. Gallen 
in relation to patients who had undergone mastectomy. In this 
case, in the concurring view of the St. Gallen panellists 
(> 70%) and the German experts, a complete axillary dissec-
tion should (still) be performed.
Radiation Therapy Following Breast-Conserving Operations
With a clear majority (68%), the panellists in St. Gallen 
confirmed radiation therapy as a standard following a breast-
conserving operation for patients with R0-resected ductal car-
cinoma in situ (DCIS). The German experts agreed with this 
opinion. Postoperative irradiation reduces the local relapse 
risk by more than half. In the case of older DCIS patients 
(≥ 70 years), the majority of panellists voted that irradiation 
Fig. 1. AGO recommendation regarding axillary lymph node dissection 
(www.ago-online.de).
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fact that the meta-analysis of the Early Breast Cancer Trial-
ists’ Collaborative Group [5] for patients following adjuvant 
chemotherapy has shown no effect of an OFS. In contrast 
to the St. Gallen panellists, the German experts view the 
combination of OFS plus aromatase inhibitor not to be an 
alternative. There was a controversial discussion amongst the 
German experts concerning the question of whether, in view 
of the spectrum of side effects, the combination of tamoxifen 
with anticoagulation is an option.
Postmenopausal Patients
A change was seen in the results of voting compared with 
St. Gallen 2009 with regard to the value of aromatase inhibi-
tors (AI) in postmenopausal patients with hormone-sensitive 
early carcinoma of the breast. In response to the question 
of whether fundamentally all postmenopausal patients must 
receive an AI in the course of anti-hormonal treatment, only 
50% voted yes. From the German perspective, most post-
menopausal women should receive an AI for at least 2–3 
years (cf. AGO recommendation 2011). A clear majority of 
panellists (79%) voted in favour of postmenopausal patients 
with affected lymph nodes in general receiving an AI. The 
German experts agreed with this statement.
Nonetheless, the St. Gallen panellists voted with a clear 
majority that the only administration of tamoxifen is still, as 
previously, an option. From the German perspective, an indi-
cation for the administration of tamoxifen can exist, for exam-
ple, in the case of older patients, in the event of intolerance to 
AI, with severe osteoporosis, or when there is a low risk of 
relapse (small tumour, pN0, G1). In a later question, 98% of 
the St. Gallen panellists view tamoxifen to be an alternative in 
the case of intolerability to an AI. The German experts agree 
with this statement.
If an AI is indicated, 52% of the St. Gallen panellists would 
not give it upfront. The German working group commented 
that there are valid study data for both upfront use and also 
the sequential administration of AI before or after tamoxifen, 
so that all 3 options are possible in everyday clinical practice.
There is agreement that AI should not be given for longer 
than 5 years. Also, in the case of patients with involved lymph 
nodes, the majority of panellists (55%) rejected long-term 
therapy with AI. The German experts agreed, as there are no 
data available from controlled clinical studies that justify the 
use of AI for more than 5 years, and recommend to partici-
pate in studies such as the SOLE study (www.germanbreast-
group.de). In the case of pre- and perimenopausal patients, 
AI are not indicated.
The Significance of CYP2D6 Determination and the HER2 
Receptor
There was agreement that CYP2D6 determination has no 
relevance for the decision of whether postmenopausal pa-
tients should receive an AI or tamoxifen. Data regarding 
CYP2D6 determination in the case of premenopausal patients 
given by the St. Gallen panellists with regard to postoperative 
radiation for patients who have undergone mastectomy with 
1–3 affected lymph nodes, as well as for those without lymph 
node involvement and ≥ pT2 tumours. In accordance with the 
AGO recommendation 2011, the German experts recom-
mend, in the case of 1–3 involved lymph nodes, to make the 
indication dependent on the age of the patient and other risk 
factors (LOE 1a GR+). The voting results with regard to 
young patients (< 45 years) or those with extended vascular 
invasion (lymph- or haemangiosis carcinomatosa, i.e. L1 and/
or V1) and/or 1–3 involved lymph nodes was clearly more 
heterogeneous. With a narrow majority, in both situations, 
routine postoperative radiation following mastectomy was 
recommended. In the opinion of the German experts, the 
clinical situations described are ‘can’ criteria. Because of the 
lack of clinical data, the indication for postoperative radiation 
should be performed on an individual basis in these cases 
(cf. AGO recommendation 2011).
Adjuvant Antihormonal Treatment
Premenopausal Patients
A hormone-sensitive breast cancer is defined by ≥ 1% of the 
tumour cells with ER+ and/or PgR+. For a premenopausal 
patient with hormone-sensitive cancer, both treatment with 
tamoxifen (± chemotherapy), as well as a combination of 
tamoxifen plus ovarian function suppression (OFS) are possi-
ble. The combination of tamoxifen plus OFS (luteinizing hor-
mone-releasing hormone (LHRH) agonist) is, however, not 
superior to the administration of tamoxifen alone (± chemo-
therapy). In this case, the German working group agreed for 
the given situation with the majority of the St. Gallen panel-
lists. The German experts substantiated their view by noting 
that, on the basis of the available data, treatment with 
tamoxifen alone was sufficient, independent of whether 
therapy-induced amenorrhoea is present or not. The combi-
nation of tamoxifen plus OFS following adjuvant chemo-
therapy is, if at all, an option for young patients under 
40 years of age. The question of whether patients would actu-
ally benefit from the additional administration of a LHRH 
analogue will be shown by the SOFT and TEXT studies.
More than 70% of the St. Gallen panellists consider OFS 
alone to be a therapy option for premenopausal patients when 
there are contraindications against tamoxifen. From the 
German perspective, the only use of OFS as an alternative 
to tamoxifen is, for example, in women with a clinically rele-
vant contraindication to tamoxifen such as thrombosis or 
embolism.
The question of whether OFS alone is also an alternative 
following prior adjuvant chemotherapy was viewed controver-
sially. When no other anti-hormonal therapy is available, 
there was a majority agreement and reference was made to 
the uncertain data situation. Attention should be drawn to the 
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abstentions. Both votes were rejected by the German experts 
who mentioned the positive clinical data situation. There is 
currently no adjuvant indication for the RANK ligand deno-
sumab. Study data justifying the substitution of zoledronate 
by denosumab in the adjuvant situation are not available.
Adjuvant Chemotherapy
Chemotherapy in Patients with Positive Hormone  
Receptor Status
The focus of consideration with regard to adjuvant chemo-
therapy in St. Gallen was the influence of conventional risk 
factors and biological variables on the decision for therapy. 
According to the St. Gallen meeting, independent of the 
nodal status, reasons for adjuvant chemotherapy are grading 
(G3 tumour), increased Ki-67 values (> 14%), low hormone 
receptor expression (< 50%), positive HER2 status and inva-
sive ductal triple-negative carcinoma of the breast (TNBC: 
ER–, PgR–, HER2–). Of note, special histological forms such 
as adenoid cystic cancer, metaplastic and medullary cancer 
are also negative for all 3 receptors, but do, however, show 
a good prognosis. These special forms are not allocated to the 
TNBC.
The German experts comment that grading in clinical 
studies is one of the most siginificant prognostic and predic-
tive factors. The proliferation factor Ki-67 can, especially in 
the case of hormone receptor-positive tumours, be an addi-
tional criterion for adjuvant chemotherapy (distinguishing 
between luminal A and B tumours). Problematic are – as 
already discussed – the heterogeneous Ki-67 tests and hetero-
geneous cut-off value for high proliferation.
The cut-off value  used in St. Gallen for a low hormone 
receptor expression of < 50% is, from the German point of 
view, arbitrary. There are no prospective data available 
regarding this point. Basically, the following rule applies: the 
lower the hormone receptor expression, the greater is the 
efficacy of chemotherapy. From the German perspective, 
evidence of HER2 overexpression in pT1b tumours is, inde-
pendent of the nodal status, an indication for chemotherapy. 
This is true independent of ER status (cf. AGO/NCCN rec-
ommendation). Also, the presence of a TNBC implies a clear 
indication for chemotherapy. However, the German experts 
stated that there are no data available for benefit of adjuvant 
chemotherapy in TNBC < 1 cm. In this case, the decision 
regarding therapy should be based on additional factors, such 
as the age of the patient, grading, or proliferation factor.
Controversial: Nodal Status
Lymph node status per se as an indicator for the additional 
use of chemotherapy was rejected by 60% of the St. Gallen 
panellists. The voting was viewed controversially by the Ger-
man experts. Lymph node status still remains the strongest 
prognostic parameter, but is, however, not a good predictive 
are not available. The German experts recommend patients to 
participate in the register study in Tübingen.
The question whether the therapy decision for or against 
AI or tamoxifen should be made dependent on biological 
tumour variables was voted controversially. From the Ger-
man viewpoint, this corresponds to the clinical reality, as 
prospective data from controlled clinical studies are lacking. 
As a rule, postmenopausal patients with hormone-sensitive 
carcinomas of the breast and an increased risk profile receive 
an AI.
The German experts agreed with the St. Gallen panellists 
that patients with hormone-sensitive and, at the same time, 
HER2-overexpression additionally need chemotherapy. In 
postmenopausal patients, HER2 overexpression should have 
no influence on the subsequent decision regarding endocrine 
therapy. At present, there are no validated study data availa-
ble that indicate that patients benefit more from AI than from 
tamoxifen. There is also agreement that overweight is not a 
contraindication to AI. The German experts pointed out that 
the data relevant to this question are contradictory.
The Adjuvant Use of Bisphosphonates
The adjuvant use of bisphosphonates has again become the 
subject of discussion as a result of the AZURE data. None-
theless, the German experts emphasise the fact that patients 
can benefit from the use of bisphosphonates independent of 
their menopausal status and other adjuvant therapy. For the 
majority of patients additional adjuvant treatment with a 
bisphosphonate reduces the probability of a relapse, which in 
some studies was also reflected in a lower rate of mortality. It 
is currently postulated that, in particular, oestrogen-deficient 
patients (i.e. with an activated bone metabolism) appear to 
benefit from the administration of adjuvant bisphosphonates. 
These are, for example, patients who have been postmeno-
pausal for more than 5 years.
The questions raised for voting in St. Gallen focussed on 
the bisphosphonate zoledronate. The question of whether 
premenopausal patients should, in addition to adjuvant endo-
crine therapy with or without OFS, receive zoledronate was 
rejected by the majority (81%) of the St. Gallen panellists. 
The German experts are in agreement but pointed out that an 
oncologic advantage for the additional administration of 
bisphosphonates in patients without adjuvant chemotherapy 
has been validated. The St. Gallen panellists also rejected the 
additional administration of zoledronate for postmenopausal 
patients. The German experts do not agree with this second 
vote referring to the clinical data evidence. The AGO guide-
line 2011 gives a clear recommendation in this context for 
postmenopausal patients (zoledronate).
In 2 further votes, the St. Gallen panellists rejected the 
proposition that zoledronate – given every 6 months in addi-
tion to adjuvant endocrine therapy – improves the disease-
free survival. For patients who have been postmenopausal for 
some years, 44% of the panellists still rejected this, with 23% 
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liferation. As a rule, they receive chemotherapy followed by 
endocrine treatment. The St. Gallen panellists voted in favour 
of giving these patients an anthracycline-containing and 
taxane-containing regimen. There is agreement from the 
German experts. From retrospective analyses, taxane-/anthra-
cycline-containing regimens are superior to anthracycline-
containing therapy alone. The rare case of a luminal B tumour 
with HER2 overexpression requires chemotherapy with 
trastuzumab.
Basal-like cancer has an un favourable tumour biology. The 
St. Gallen panellists also voted in favour of treating these 
patients with an anthracycline-/taxane-containing chemo-
therapy. The German experts commented that the regimen 
used should  contain anthracyclines and taxanes.
The proposal to treat patients with invasive ductal TNBC 
with a dose-dense chemotherapy was approved by a majority 
(52%) in St. Gallen. At present, only few subgroup data relat-
ing to this point are available. Advantages for patients with 
TNBC have for example been demonstrated in a dose-dense 
therapy study from Germany [7]. No indication exists in 
patients with invasive ductal TNBC for an antiangiogenic 
therapy in addition to chemotherapy. Likewise, there are 
no prospective data available regarding the use of platinum 
compounds in ductal invasive TNBC.
Neoadjuvant Chemotherapy
The neoadjuvant therapy concept was further developed and 
validated, especially in Germany, in the context of large pro-
spective clinical studies. It is now well established and interna-
tionally accepted for the treatment of patients with early 
breast cancer. German study data have been cited in numer-
ous lectures at international congresses. The focus of atten-
tion in neoadjuvant therapy in St. Gallen was on establishing 
the indication and the choice of drugs. In contrast to the ques-
tions raised in relation to adjuvant therapy, tumour biology 
received hardly any consideration.
Indication for Neoadjuvant Therapy
In the view of the majority (60%) of the St. Gallen panellists, 
the main aim of neoadjuvant therapy is the improvement of 
surgical options, especially increasing the rate of breast-con-
serving operations. The German experts agreed, but drew 
attention to other goals. The response associated with the 
neoadjuvant concept enables early individual proof of the 
value of a therapy and therefore contributes to a greater indi-
vidualisation of treatment and the early introduction of new 
therapy concepts. Moreover, neoadjuvant therapy facilitates 
the evaluation of response and outcome. The achievement of 
a pathologically complete remission (pCR) in HER2-positive 
tumours and TNBC is considered to be a strong predictive 
marker for long survival. The German experts and St. Gallen 
panellists agreed that a neoadjuvant therapy should be used 
factor. A positive nodal status implies an increased risk, but 
does not result automatically in an indication for adjuvant 
chemotherapy. The problem in everyday clinical routine is in 
the case of patients with 1–3 involved lymph nodes (medium 
risk) following complete axillary dissection, who have an 
excellent outcome with a 5-year survival rate of 95% with 
adequate anthracycline/taxane-containing chemotherapy 
(WSG/AGO study [6]). However, there is also the danger of 
overtreatment. The German experts see the need of identify-
ing a subgroup in patients with 1–3 affected lymph nodes that 
does not need chemotherapy. Possibly, in this case, optimised 
prognostic and predictive factors such as gene expression 
analyses will bring greater clarity in the future. At present, 
one should focus on the age of the patient and the tumour 
biology. There is agreement that ≥ 3 involved lymph nodes 
following complete axillary dissection represent a clear indi-
cation for chemotherapy.
Lymphovascular Invasion
There are no prospective data available regarding the value of 
lymphovascular invasion as a criterion for the use of chemo-
therapy. The general opinion is equally controversial. From 
the German point of view, lymphovascular invasion can be of 
value in individual cases for the use of chemotherapy, for 
example, N0 patients.
Gene Expression Analyses
Since St. Gallen 2009, the retrospective data situation regard-
ing the value of gene expression analyses using Oncotype DX 
and Mammaprint for chemotherapy decision in the case of 
patients with hormone receptor-positive cancer, has been 
extended. This also includes, for example, patients with 1–3 
involved lymph nodes. The German experts agreed with this 
year’s vote of the St. Gallen panellists that both genetic tests 
could be of value in addition to classical parameters. Once 
more, the German experts emphasized that a general recom-
mendation outside clinical studies is not justified as, up until 
now, no data from prospective studies are available.
The Influence of the Phenotype on the Therapy Decision
In St. Gallen, numerous votes related to the phenotype 
(table 1) on the chemotherapy decision. From the German 
point of view, only a few retrospective analyses and no pro-
spective data are available and phenotype itself is not a pre-
dictor for a particular chemotherapy. Luminal A cancer 
includes classic endocrine-sensitive tumours. The St. Gallen 
panellists and the German experts agreed that this phenotype 
probably requires no chemotherapy. The therapy of choice 
for patients with luminal A tumours is endocrine treatment. 
For luminal A patients, there is no preferred chemotherapy 
regimen, should it be indicated in rare cases.
Hormone receptor-positive patients with luminal B cancer 
have an increased risk of relapse and are considered to be 
chemotherapy-sensitive because of the increased rate of pro-
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therapy option in a neoadjuvant setting for the treatment of 
patients with HER2-positive tumours. The pathologic com-
plete remission of 40–50% in these patients correlates with an 
excellent outcome [10]. The use of this therapy approach in 
clinical studies is recommended.
Neoadjuvant Endocrine Therapy
There is agreement that neoadjuvant endocrine therapy alone 
with highly hormone-sensitive tumours is fundamentally 
possible. It is still unclear how long the therapy should go on 
for. This is also reflected in the results of voting: 15% voted 
for 3–4 months, 39% for 4–8 months, and 46% until the 
best therapy response has been achieved. In contrast, the 
German working group commented, contrary to the majority 
of panellists in St. Gallen, that the best therapy results are 
achieved with a 4-month AI therapy. The duration of therapy 
is controversially discussed.
HER2-Positive Breast Cancer
The German experts pointed out that quality-assured HER2 
testing is an indispensable prerequisite for anti-HER2 
therapy. The participation in validated quality controls and 
the application of ASCO/CAP guidelines is recommended.
A preference for a particular chemotherapy regimen for 
treating a HER2-positive early breast cancer was rejected by 
the majority of St. Gallen panellists. The German experts 
agreed, but noted that anthracycline- and taxane-containing 
chemotherapy regimens, independent of the nodal status of 
the patient, are standard for the treatment of HER2-positive 
early breast cancer. The St. Gallen panel confirmed this: 98% 
of the panellists supported the view that chemotherapy should 
contain an anthracycline, 75% of the panellists judged this to 
be essential, and 83% supported the use of a taxane as obliga-
tory. In addition to this, the German working group also saw 
the anthracycline-free TCbH regimen (docetaxel, carbo-
platinum, trastuzumab) as a valid therapy option in the case 
of patients with an anthracycline contraindication [8].
All panellists (100%) voted for trastuzumab for 1 year as 
(neo)adjuvant chemotherapy in patients with HER2-over-
expression. The German experts agreed without reservations. 
A clear majority of the St. Gallen panellists (79%) also 
approved this for patients with HER2-positive breast cancer 
between 5 mm and 1 cm and pN0. From the German point of 
view, this applies without restriction in the case of patients 
with positive nodal status, and should be taken into considera-
tion for pN0 patients in accordance with the AGO guideline 
2011 and the NCCN guidelines.
There is also agreement that trastuzumab is only indicated 
together with chemotherapy. The St. Gallen panellists espe-
cially considered the simultaneous and optional as well as the 
sequential administration of trastuzumab as a valid option in 
with the highest chance of response (cf. AGO recommenda-
tion 2011).
Similar to the adjuvant situation, neoadjuvant chemo-
therapy is less effective in patients with a low risk profile, for 
example, a tumour with a low proliferation rate. Overall, 64% 
of the panellists in St. Gallen confirmed this. A low prolifera-
tion rate is to be assumed, for example, with a low Ki-67 
value. For the decision of whether neoadjuvant chemotherapy 
or an endocrine therapy is indicated, the German working 
group recommended an orientation based on the phenotype 
of the tumour, which implies the proliferation behaviour. 
Correspondingly, patients with a luminal A breast cancer 
can also receive neoadjuvant and endocrine therapy. Over-
treatment should, however, be avoided.
A total of 77% of the St. Gallen panellists rejected the use 
of neoadjuvant chemotherapy in the case of patients with 
highly endocrine-sensitive carcinoma of the breast, such as 
(pure) lobular carcinoma. The German working group agreed 
with this. The German experts noted that pure lobular carci-
nomas, which are highly endocrine-sensitive, show favourable 
grading (G1/2) and are HER2-negative; hence, they most 
likely do not benefit from neoadjuvant therapy.
Substance Selection for Neoadjuvant Chemotherapy
In the choice of substance, the overwhelming majority of 
panellists in St. Gallen (82%) voted for neoadjuvant chemo-
therapy favouring the use of anthracycline-containing and 
taxane-containing regimens. Compared to the voting from 
2 years ago, the acceptance of taxanes has increased by 20%. 
The German working group also interpreted this to be an in-
dication of the good acceptance of the results of the German 
study. With a large majority (86%), the panellists in St. Gallen 
voted in favour of using an adjuvant standard chemotherapy 
regimen also in the neoadjuvant setting. In Germany, this has 
been recommended since 2006 in the AGO recommendation 
and the S3 guideline.
Therapy of HER2 Overexpressing Breast Cancer
With HER2 overexpression, an anti-HER2 therapy is always 
indicated in addition to neoadjuvant chemotherapy. Overall, 
87% of the panellists in St. Gallen confirmed this. The Ger-
man experts agreed with the comment that the chemotherapy 
should be anthracycline-/taxane-containing. The German ex-
perts had a strong debate as to whether trastuzumab should 
be used simultaneously with anthracycline or at the beginning 
of the taxane-containing therapy. Prospective study data are 
available for both options. The minimal consensus of the 
German experts is that the decision should be made using the 
cardiac risk profile of the patient. In the case of simultaneous 
administration of anthracycline, before and during treatment, 
regular cardiac monitoring should be carried out.
The German experts agreed with the St. Gallen panellists 
that the dual HER2 blockade is currently still not a validated 
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addition to chemotherapy. The majority of the German ex-
perts agreed with this opinion, but mentioned the potentially 
increased cardiac side effects with the simultaneous adminis-
tration of trastuzumab and anthracyclines, which can be 
diminished by sequential application or the use of TCbH.
There are currently no data available concerning the 
question of whether to use trastuzumab for less than or more 
than 1 year. Corresponding prospective clinical studies (6 vs. 
12 months or 12 vs. 24 months) are still in progress or in the 
stage of evaluation. There is therefore agreement that a 
shorter or longer duration is currently not an option in every-
day clinical practice. Only for countries with limited re-
sources, the majority of St. Gallen panellists (71%) admit that 
administration of trastuzumab over a shorter period of time 
(< 1 year) is possible, in order to prevent a situation in which 
trastuzumab will be withheld from patients with HER2-posi-
tive tumours. Following a debate, the German experts agree 
but mentioned that this is not evidence-based and has no 
validity for Germany. The standard is to give trastuzumab for 
1 year in accordance with the available data and licensing for 
the substance.
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There is also no indication for the use of trastuzumab alone 
± endocrine therapy. However, the St. Gallen panellists voted 
in favour of this being an option for patients with contraindi-
cations to chemotherapy. The German working group rejects 
this statement. The recommendation is – whenever possible – 
to use the synergy between trastuzumab and chemotherapy.
Male Breast Cancer
In rare cases, men also develop breast cancer (about 400– 
500 new cases each year in Germany). The standard endo-
crine therapy is tamoxifen. An indication for AI does not 
exist for men. The German working group mentions the 
study to be started in the near future called MALE study 
(www.germanbreastgroup.de), in which the use of AI will be 
investigated.
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